AbbVie Inc
ABBVHealthcare|Drug Manufacturers - General|USA
$248.08
-1.83 (-0.73%)
DCF (FCF)
$102.04
Earnings Power
$55.26
About
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Stock Price
+27.2%(1Y)
Pipeline Summary
567 total trials151
Phase 1
149
Phase 2
131
Phase 3
23
Phase 4
Completed: 372Recruiting: 64Active: 61Terminated: 36Withdrawn: 18Unknown: 5NOT_YET_RECRUITING: 4NO_LONGER_AVAILABLE: 6ENROLLING_BY_INVITATION: 1
Active Trials (125)
A Study of Virtual Reality and Linaclotide for IBS-C
NCT05796388Irritable Bowel Syndrome With Constipation
N/ARecruiting
Enrollment: 65 participants
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
NCT02993523Acute Myeloid Leukemia (AML)
Phase 3Active
Enrollment: 443 participants
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
NCT05144243Acute Myeloid Leukemia (AML)
Phase 4Active
Enrollment: 44 participants
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
NCT06522386Mantle Cell Lymphoma
Phase 2Active
Enrollment: 50 participants
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
NCT04567550Diabetic Retinopathy (DR)
Phase 2Active
Enrollment: 139 participants
BioScore
6.8/10
Buy
Ownership
Recent Insider Trades
Siatis Perry CSELL
2026-03-0218,668 shares @ $234.39
Siatis Perry CSELL
2026-02-2522,381 shares @ $230
SALEKI-GERHARDT AZITASELL
2025-08-1242,370 shares @ $198.42
Donoghoe NicholasSELL
2025-08-0513,295 shares @ $198.51
Stewart Jeffrey RyanSELL
2025-03-3158,832 shares @ $210.08
Recent News
2026-07-11 00:24:48
2026-07-10 18:35:02
2026-07-10 13:56:48
2026-07-10 13:44:36
2026-07-10 13:02:24
Data last updated: Jul 12, 2026, 07:23 PM